Toward beta cell replacement for diabetes
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The discovery of insulin more than 90 years ago introduced a life-saving treatment for patients with type 1 diabetes, and since then, significant progress has been made in clinical care for all forms of diabetes. However, no method of insulin delivery matches the ability of the human pancreas to reliably and automatically maintain glucose levels within a tight range. Transplantation of human islets or of an intact pancreas can in principle cure diabetes, but this approach is generally reserved for cases with simultaneous transplantation of a kidney, where immunosuppression is already a requirement. Recent advances in cell reprogramming and beta cell differentiation now allow the generation of personalized stem cells, providing an unlimited source of beta cells for research and for developing autologous cell therapies. In this review, we will discuss the utility of stem cell-derived beta cells to investigate the mechanisms of beta cell failure in diabetes, and the challenges to develop beta cell replacement therapies. These challenges include appropriate quality controls of the cells being used, the ability to generate beta cell grafts of stable cellular composition, and in the case of type 1 diabetes, protecting implanted cells from autoimmune destruction without compromising other aspects of the immune system or the functionality of the graft. Such novel treatments will need to match or exceed the relative safety and efficacy of available care for diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In search of the ‘missing self’: MHC molecules and NK cell recognition
Ljunggren, H.-G., & Kärre, K. (1990) · Immunology Today · doi:10.1016/0167-5699(90)90097-s · Cited by 2,687 · cited 1×
“As HLA is an essential component of the antigen presentation mechanism, this result is not surprising, but the downside is that the complete ablation of HLA expression usually causes cells to be targeted by natural killer (NK) cells (Ljunggren & Karre, 1990).”
Warren, L., Manos, P. D., Ahfeldt, T., Loh, Y.-H., Li, H., Lau, F., Ebina, W., Mandal, P. K., Smith, Z. D., Meissner, A., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.08.012 · Cited by 2,662
Generation of Functional Human Pancreatic β Cells In Vitro
Pagliuca, F. W., Millman, J. R., Gürtler, M., Segel, M., Van Dervort, A., Ryu, J. H., Peterson, Q. P., Greiner, D., & Melton, D. A. (2014) · Cell · doi:10.1016/j.cell.2014.09.040 · Cited by 2,025 · cited 5×
“The generation of personalized pluripotent stem cells by either nuclear transfer or factor-mediated reprogramming, and the development of improved protocols for differentiation into beta cells (Pagliuca et al , 2014; Rezania et al , 2014), has moved us closer than ever to this goal.”
InfluentialIn vivo reprogramming of adult pancreatic exocrine cells to β-cells
Zhou, Q., Brown, J., Kanarek, A., Rajagopal, J., & Melton, D. A. (2008) · Nature · doi:10.1038/nature07314 · Cited by 2,010 · cited 1×
“For instance, Zhou and colleagues found that ectopic expression of Pdx1, MafA, and Ngn3 in pancreatic exocrine cells in vivo converted them into beta cells in mice (Zhou et al , 2008).”
Kroon, E., Martinson, L. A., Kadoya, K., Bang, A. G., Kelly, O. G., Eliazer, S., Young, H., Richardson, M., Smart, N. G., Cunningham, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1393 · Cited by 1,843 · cited 2×
“This is particularly relevant, as uncontrolled differentiation and growth, so-called teratomas, have often been observed in mice grafted with stem cell-derived pancreatic precursors (Kroon et al , 2008; Kelly et al , 2011).”
Efficient differentiation of human embryonic stem cells to definitive endoderm
D'Amour, K. A., Agulnick, A. D., Eliazer, S., Kelly, O. G., Kroon, E., & Baetge, E. E. (2005) · Nature Biotechnology · doi:10.1038/nbt1163 · Cited by 1,730
Extracellular matrix as a biological scaffold material: Structure and function
BADYLAK, S., FREYTES, D., & GILBERT, T. (2009) · Acta Biomaterialia · doi:10.1016/j.actbio.2008.09.013 · Cited by 1,671
Self-citationReversal of diabetes with insulin-producing cells derived in vitro from human pluripotent stem cells
Rezania, A., Bruin, J. E., Arora, P., Rubin, A., Batushansky, I., Asadi, A., O'Dwyer, S., Quiskamp, N., Mojibian, M., Albrecht, T., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.3033 · Cited by 1,575 · cited 3×
“To generate functional monohormonal beta cells in vitro , Pagliuca and colleagues as well as Rezania and colleagues manipulated additional pathways implicated in the development of the pancreas (Pagliuca et al , 2014; Rezania et al , 2014).”
Somatic coding mutations in human induced pluripotent stem cells
Gore, A., Li, Z., Fung, H.-L., Young, J. E., Agarwal, S., Antosiewicz-Bourget, J., Canto, I., Giorgetti, A., Israel, M. A., Kiskinis, E., et al. (2011) · Nature · doi:10.1038/nature09805 · Cited by 1,273
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012864 · Cited by 1,222 · cited 1×
“Further, therapies aimed at inhibiting the autoimmune reaction in recent-onset T1D are only able to transiently maintain C-peptide levels in the blood, but not restore normal levels (Herold et al , 2002; Keymeulen et al , 2005).”
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
Keymeulen, B., Vandemeulebroucke, E., Ziegler, A. G., Mathieu, C., Kaufman, L., Hale, G., Gorus, F., Goldman, M., Walter, M., Candon, S., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043980 · Cited by 1,099
Badylak, S. F., Taylor, D., & Uygun, K. (2011) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071910-124743 · Cited by 1,041 · cited 1×
“Interactions between different cell types and vascularization, as well as the 3D arrangement, of the cells play an important role in tissue reconstruction (Badylak et al , 2011; Goh et al , 2013).”
Vukicevic, S., Kleinman, H. K., Luyten, F. P., Roberts, A. B., Roche, N. S., & Reddi, A. H. (1992) · Experimental Cell Research · doi:10.1016/0014-4827(92)90397-q · Cited by 696
Recovery from diabetes in mice by β cell regeneration
Nir, T., Melton, D. A., & Dor, Y. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32959 · Cited by 595 · cited 1×
“In mice, beta cell mass can recover after ablating most cells with a toxin (Nir et al , 2007) or if the auto-immune reaction in NOD mice is halted after beta cell destruction has commenced (Nishio et al , 2006).”
Rezania, A., Bruin, J. E., Riedel, M. J., Mojibian, M., Asadi, A., Xu, J., Gauvin, R., Narayan, K., Karanu, F., O’Neil, J. J., et al. (2012) · Diabetes · doi:10.2337/db11-1711 · Cited by 582 · cited 1×
“Based on these studies, a number of groups have succeeded in generating insulin-producing cells with an efficiency of about 25% (Kelly et al , 2011; Nostro et al , 2011; Kunisada et al , 2012; Rezania et al , 2012, 2013; Schulz et al , 2012; Hua et al , 2013; Shang et al , 2014).”
Todd, J. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.04.001 · Cited by 560
Extracellular matrix, integrins, and growth factors as tailors of the stem cell niche
Brizzi, M. F., Tarone, G., & Defilippi, P. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.07.001 · Cited by 412
Oram, R. A., Jones, A. G., Besser, R. E. J., Knight, B. A., Shields, B. M., Brown, R. J., Hattersley, A. T., & McDonald, T. J. (2014) · Diabetologia · doi:10.1007/s00125-013-3067-x · Cited by 298 · cited 1×
“Upon diagnosis, patients show an age-dependent loss of 40 – 85% of their beta cell mass (Klinke, 2008), and a small amount of beta cells remain for many years in the majority of T1D patients (Oram et al , 2014).”
Toward the development of a global induced pluripotent stem cell library
Turner, M., Leslie, S., Martin, N. G., Peschanski, M., Rao, M., Taylor, C. J., Trounson, A., Turner, D., Yamanaka, S., & Wilmut, I. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.08.003 · Cited by 245 · cited 1×
“Others proposed the development of haplotype-matched array of stem cell lines to reduce allo-immunity (Turner et al , 2013).”
Type 1 diabetes: translating mechanistic observations into effective clinical outcomes
Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology · doi:10.1038/nri3422 · Cited by 237
Vendrame, F., Pileggi, A., Laughlin, E., Allende, G., Martin-Pagola, A., Molano, R. D., Diamantopoulos, S., Standifer, N., Geubtner, K., Falk, B. A., et al. (2010) · Diabetes · doi:10.2337/db09-0498 · Cited by 215
Recent Lessons Learned From Prevention and Recent-Onset Type 1 Diabetes Immunotherapy Trials
Staeva, T. P., Chatenoud, L., Insel, R., & Atkinson, M. A. (2013) · Diabetes · doi:10.2337/db12-0562 · Cited by 91 · cited 3×
“…pathways with biologics has proven beneficial in a number of major autoimmune diseases, but anti-TNF and anti-IL1 b have shown no or poor efficacy on their own in T1D, suggesting that simply blocking inflammation is insufficient to restore immune regulation in this disease (Staeva et al , 2013).”
Influential
Cited by
Generation of insulin-producing pancreatic β cells from multiple human stem cell lines
Hogrebe, N. J., Maxwell, K. G., Augsornworawat, P., & Millman, J. R. (2021) · Nature Protocols · doi:10.1038/s41596-021-00560-y · Cited by 211
Milajerdi, A., Abbasi, F., Mousavi, S. M., & Esmaillzadeh, A. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.03.037 · Cited by 64
Grindheim, J. M., Nicetto, D., Donahue, G., & Zaret, K. S. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.041 · Cited by 35
Metadata
- Authors
- Johannesson, B., Sui, L., Freytes, D. O., Creusot, R. J., & Egli, D.
- Venue
- The EMBO Journal
- Published
- 2015-03-02
- Volume
- 34
- Issue
- 7
- Pages
- 841-855
- ISSN
- 0261-4189 (ISSN-L)
- 1460-2075
- OpenAlex
- W2122178825
- Cited by
- 44
- References
- 22
- FWCI
- 5.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.